Prolymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Prolymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Acalabrutinib in Patients with Chronic Lymphocytic Leukemia, Richter’s Syndrome, or Prolymphocytic Leukemia https://clinicaltrials.eu/trial/study-on-the-effects-of-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia-richters-syndrome-or-prolymphocytic-leukemia/ Wed, 29 Apr 2026 14:59:12 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia-richters-syndrome-or-prolymphocytic-leukemia/ This clinical trial is focused on studying the effects of a medication called acalabrutinib, also known by its code name ACP-196. The trial is designed to explore its use in treating certain types of blood cancers, specifically Chronic Lymphocytic Leukemia (CLL), Richter’s Syndrome, and Prolymphocytic Leukemia. These are conditions where the body produces abnormal white blood cells, which can affect the immune system and overall health. The medication is provided in two forms: film-coated tablets and hard capsules, both taken orally.

The purpose of the study is to determine the safety and appropriate dosage of acalabrutinib for patients with these conditions. Participants in the trial will receive the medication in increasing doses to find the most effective and safe amount. The study will also look at how the body processes the medication and its effects on the disease. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will be monitored closely to observe how their bodies respond to the treatment. This includes regular check-ups and tests to ensure their safety and to gather information on the medication’s impact. The trial aims to provide valuable insights into the potential benefits of acalabrutinib for treating these specific types of leukemia and related conditions.

]]> Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-entrectinib-and-other-drug-combinations-for-patients-with-advanced-solid-tumors-multiple-myeloma-or-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:30:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-entrectinib-and-other-drug-combinations-for-patients-with-advanced-solid-tumors-multiple-myeloma-or-non-hodgkin-lymphoma/ This clinical trial is focused on studying the effects of targeted anti-cancer drugs on patients with advanced solid tumors, non-Hodgkin lymphoma, or multiple myeloma. These are types of cancers that have spread or are difficult to treat with standard therapies. The study aims to explore how these drugs, which are already available on the market, can be used to treat these cancers based on specific genetic or protein markers found in the tumors. These markers can help predict how well a patient might respond to a particular drug.

The trial includes a variety of medications, such as Rozlytrek, Cabometyx, Lenvima, Tepmetko, Retsevmo, Vectibix, Xalkori, Zejula, Tarceva, Inlyta, Pemazyre, Stivarga, Cotellic, Mekinist, Rubraca, Tecentriq, Keytruda, Tasigna, Erivedge, Talzenna, Sutent, Imfinzi, Avastin, Opdivo, Piqray, Lynparza, Zelboraf, Herceptin, Perjeta, Yervoy, Tafinlar, Lorviqua, and Vizimpro. Some of these drugs have code names, such as XL-184 for Cabometyx and LOXO-292 for Retsevmo. The study also involves the use of a placebo for comparison.

Participants in the study will receive one of these medications based on the specific characteristics of their cancer. The study will monitor the effects of the treatment over time, looking at how the cancer responds and any side effects that may occur. The goal is to better understand which drugs work best for different types of cancer and to provide patients with access to potentially effective treatments. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the long-term effects and benefits of these treatments.

]]>